Flexibility And Agility Key To Speedy UK COVID Vaccine Approval
MRHA Head Insists No Compromises Were Made In Review Of Pfizer/BioNTech Vaccine
Executive Summary
The flexibility and agility of parallel teams of scientists and clinicians who worked around the clock were key to speedy UK approval of the COVID-19 vaccine, according to UK agency head June Raine. Canada has also just announced that it has approved the Pfizer/BioNTech vaccine.
You may also be interested in...
The Absurd COVID-19 Vaccine Regulatory Race
Donald Trump is no longer the only one who thinks the US FDA is moving too slow on allowing broad access to COVID-19 vaccine candidates. But before the narrative that FDA’s caution cost lives takes root, let’s remember the facts: the key milestone isn’t when an effective vaccine is authorized, but when supplies are sufficient to mount an effective vaccination campaign.
Pfizer Allergy Warning Is First Test Of UK Vaccine Roll-Out
Individuals with history of significant allergic reactions are now being told not to have the vaccine after warnings were not included in healthcare professional information.
Pfizer Allergy Warning Is First Test Of UK Vaccine Roll-Out
Individuals with history of significant allergic reactions are now being told not to have the vaccine after warnings were not included in healthcare professional information.